![]() ![]() Walking stability and sensorimotor function in older people with diabetic peripheral neuropathy. Menz HB, Lord SR, St George R, Fitzpatrick RC. 2009 10(2):393–400.ĭyck PJ, Davies JL, Wilson DM, Service FJ, Melton LJ, O'Brien PC 1999 Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A, Group KS. A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: differences in demographic data and sensory symptoms. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Sumner CJ, Sheth S, Griffin JW, Cornblath DR, Polydefkis M. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. 1998 24 Suppl 3:55–65.ĭyck PJ, Albers JW, Andersen H, et al. European Association for the Study of Diabetes, Neurodiab. Guidelines for diagnosis and outpatient management of diabetic peripheral neuropathy. Current methods of the US Preventive Services Task Force: a review of the process. This study reports improved analgesic outcomes in patients with painful diabetic neuropathy who received 10-kHz spinal cord stimulation versus those who received best medical therapy. Effect of high-frequency (10-kHz) spinal cord stimulation in patients with painful diabetic neuropathy: a randomized clinical trial. Petersen EA, Stauss TG, Scowcroft JA, et al. ![]() ![]() Capsaicin 8% dermal patch: a review in peripheral neuropathic pain. New and developing drugs for the treatment of neuropathic pain in diabetes. Diabetic neuropathy: A Position Statement by the American Diabetes Association. Pop-Busui R, Boulton AJ, Feldman EL, et al. Epidemiology of type 2 diabetes - global burden of disease and forecasted trends. Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Papers of particular interest, published recently, have been highlighted as: Furthermore, it provides updates on the level of evidence for SCS therapy in cases of PDN refractory to conventional medical therapy. In summary, this review provides an overview of treatment options for PDN. ![]() There is level I evidence on the use of dorsal column spinal cord stimulation (SCS) for treatment of PDN, delivering either a 10-kHz waveform or tonic waveform. Additional pharmacologic modalities that are approved by the Food and Drug Administration (FDA) but are considered second-line agents include tapentadol and 8% capsaicin patch, although studies have revealed modest treatment effects from these modalities. First-line pharmacologic therapy for PDN includes gabapentinoids (pregabalin and gabapentin) and duloxetine. Intensive glycemic control with insulin in patients with type 1 diabetes may be associated with lower odds of distal symmetric polyneuropathy compared to patients who receive conventional insulin therapy. The authors appraised the literature for evidence on conservative, pharmacological, and neuromodulation treatment options for PDN. Painful diabetic neuropathy (PDN) manifests with pain typically in the distal lower extremities and can be challenging to treat. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |